Emergency approval for the use of donated plasma by healthy patients to treat people with coronavirus may be a hasty decision in the eyes of some researchers.
None of the control trials have shown that injecting an abundant plasma patient still works against Covid 19. Nevertheless, the US Food and Drug Administration announced on August 23 that the use of plasma may be beneficial. The announcement raises concerns among some experts that interventions by unprofessional therapists and non-authoritative therapists may make it difficult to determine whether plasma can actually help against covid 19.
Less than a week after the New York Times reported, attempts were made to stop the treatment of the plasma due to low and insufficient data on whether the treatment was authoritative. On August 22, President Donald Trump tweeted that he was not satisfied with the speed with which the FDA approved new vaccines and treatments to combat CoVID-19.
Although convoluted plasma appears to be safe, and there are indications that it may help people in the early stages of the disease, not enough data has been collected to say that the treatment is effective, some experts warn. What is it.
What is convalescent plasma?
Convalescent plasma is the liquid part of blood taken from people who have recovered from an infection, in this case from COVID-19. Plasma contains antibodies that people have built against the pathogen.
Is convalescent plasma safe?
It’s generally considered safe for its standard uses. So far the evidence suggests that’s the case for treating COVID-19, says Liise-anne Pirofski, an infectious diseases physician and immunologist at Albert Einstein College of Medicine in New York City.
A study of 5,000 patients published June 11 in the Journal of Clinical Investigation found serious adverse events, such as allergic reactions or transfusion-related lung injury, occurred less than 1 percent of the time. Larger studies that haven’t yet been peer-reviewed showed similar results.
Does it work?
So far, not enough data to tell.
The idea is that patients with COVID-19 can benefit from antibodies made by the body of others who have successfully fought the virus.
The research, which has helped scales to allow for emergency use, appears to have begun with a preliminary study of 35,000 patients on the Madrid XSROGRS on August 12. At the time, President Trump said the study had reduced the death toll by 35 percent, a significant proportion.
“As far as we know, 35 out of 100 people are recovering from this treatment,” added FDA Commissioner Stephen Hahn.
Researchers not only need to determine if convulsive plasma is an effective treatment. Doctors and scientists also need to know which category of patients can be helped by this treatment and which category of patients cannot.